PeptideDeepDiveWhat Is Selank Peptide? Anxiety Evidence, Nasal Spray & Legal Status
Selank is a Russian-developed anxiolytic peptide studied for anxiety-related effects and GABA signalling. Russia lists a non-prescription intranasal Selank medicine. However, Selank has no FDA approval, and we found no standard UK or EU medicine authorisation for it.
Selank is a synthetic seven-amino-acid peptide derived from tuftsin and studied mainly for anxiolytic effects. For example, a 62-patient Russian trial compared Selank with medazepam. A later 60-patient study compared it with phenazepam. However, both studies were small, and much of the evidence remains Russian-language. In addition, Russia lists a non-prescription Selank nasal medicine, while the FDA has not approved Selank in the United States.
The PeptideDeepDive Editorial Team checks human-evidence claims against PubMed-indexed studies and US regulatory claims against FDA material. For Russia, we use a current medicines reference that reproduces the registered product information. We do not list a medical reviewer because we have not verified one. Finally, this guide is educational only and does not give treatment, dosing, sourcing or legal advice.
What Is Selank Peptide?
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Russian researchers developed it from tuftsin, a naturally occurring immune-related peptide fragment. In particular, studies focus on anxiety and mood. Researchers have also explored possible effects on cognition and immune signalling.
Unlike many research peptides discussed online, Selank also exists as a registered nasal medicine in Russia. For example, a current Russian drug reference lists Selank 0.15% nasal drops as a non-prescription anxiolytic. However, that Russian status does not transfer to the United States, United Kingdom or European Union.
How Is Selank Thought to Work? GABA & Immune Modulation
Selank research often focuses on the GABA system. For example, a 2018 molecular study found that Selank can alter GABA binding through an allosteric mechanism. Earlier animal work also found changes in genes linked to GABA signalling. Together, these findings help explain why researchers describe Selank as a GABA-modulating anxiolytic peptide.
However, Selank does not have the same established human evidence base as approved anxiety medicines. Most mechanism research remains preclinical. In addition, researchers have studied immune-related effects because Selank comes from tuftsin.
What Does Selank Evidence Actually Show?
The human evidence is small but not zero. For example, a 2008 randomized trial included 62 patients with generalized anxiety disorder or neurasthenia. Researchers compared Selank in 30 patients with medazepam in 32 patients and reported similar anxiety-related effects. In addition, a 2014 study included 60 patients and compared Selank with phenazepam.
These studies are useful signals, but they have important limits. In particular, both are small Russian-language studies from the same broad research setting. They do not provide the large, independent evidence base that supports widely approved psychiatric medicines. Therefore, these studies do not prove that Selank treats anxiety.
In addition, PubMed-indexed molecular and animal studies support more research into GABA-related mechanisms. However, those studies cannot replace large human trials that measure benefits, harms and long-term outcomes.
Selank Regulatory Status: Russia vs US, UK & EU
Selank has an unusual regulatory split. On one hand, Russia has a marketed intranasal product. By contrast, the United States and the Western European systems reviewed here do not have equivalent medicine approval for Selank.
A current Russian medicines reference lists Selank 0.15% nasal drops and marks the product as available without prescription. However, that Russian status does not automatically apply in other countries.
The FDA has not approved Selank. In addition, FDA currently lists Selank acetate (TP-7) among withdrawn bulk-substance nominations. FDA also notes possible immune reactions, peptide impurities and limited human safety information.
We did not identify a standard UK marketing authorisation for Selank in the MHRA sources reviewed for this guide. Therefore, Russian approval does not count as UK medicine approval.
We did not identify a standard EMA or Irish HPRA medicine authorisation for Selank in the regulator sources reviewed here. However, national rules on import, supply and unlicensed products can differ. So, this section is not legal advice.
The FDA has not approved Selank. In addition, FDA’s current safety page places Selank acetate among withdrawn bulk-substance nominations. The agency also notes possible immune reactions, peptide impurities and limited human safety information. Therefore, older articles that call Selank simply “Category 1” or “Category 2” may no longer match the current FDA page.
Selank vs Semax: What’s the Difference?
People often group Selank and Semax together because both came from Russian peptide research and both appear in intranasal products. However, they are different molecules with different research priorities. Selank comes from tuftsin, and researchers mainly study its anxiety-related and GABA-linked effects. By contrast, Semax comes from an ACTH fragment, and researchers more often study cognitive and brain-protection pathways.
For more context, read our Semax evidence guide. In addition, see our Semax vs Selank comparison.
What Is Still Unknown About Selank?
- Whether larger, independent international trials can repeat the anxiety findings from small Russian studies
- How Selank compares with placebo in a large modern randomized trial
- Long-term safety across broader groups outside Russia
- How much purity and strength vary in unregulated research products sold online
- Whether FDA will receive or review a new Selank bulk-substance nomination
Overall, Selank has more human evidence than a purely preclinical peptide. However, it has far less evidence than an approved mainstream anxiety medicine. Therefore, its Russian nasal-medicine status does not establish FDA, MHRA or EMA approval.
Selank Peptide FAQ
Is Selank FDA-approved?
No. The FDA has not approved Selank. In addition, FDA’s current compounding safety page lists Selank acetate among withdrawn bulk-substance nominations and notes possible immune reactions and peptide impurities.
Is Selank legal in the US, UK or EU?
Selank does not have standard FDA, MHRA or EMA medicine approval. However, each jurisdiction applies different rules to possession, import, research sale and unlicensed supply. Therefore, “not approved” does not mean the same thing in every legal setting.
Is Selank available as a nasal spray?
Yes, Russia has a registered intranasal Selank product. For example, a current Russian drug reference lists 0.15% nasal drops as non-prescription. However, products sold online elsewhere do not automatically have the same regulated-drug status.
Does Selank have human clinical trials?
Yes, but the evidence is small. For example, PubMed indexes a 62-patient randomized comparison with medazepam from 2008 and a 60-patient study with phenazepam from 2014. However, these studies do not create a broad modern evidence base.
What is the difference between Selank and Semax?
Selank comes from tuftsin, and researchers mainly study anxiety-related and GABA-linked effects. By contrast, Semax comes from an ACTH fragment, and researchers more often study cognitive and brain-protection effects.
References
- Zozulia, A.A. et al. (2008), Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorder and neurasthenia — randomized controlled trial, 62 patients.
- Medvedev, V.E. et al. (2014), A comparison of the anxiolytic effect and tolerability of Selank and phenazepam — comparative clinical study, 60 patients.
- Vyunova, T.V. et al. (2018), Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity — GABA-binding and proposed anxiolytic mechanism.
- Volkova, A. et al. (2016), Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission — preclinical GABA-related gene-expression study.
- U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — Selank acetate appears under nominations that were withdrawn; FDA notes potential immunogenicity and peptide-impurity concerns.
- U.S. Food and Drug Administration, Bulk Drug Substances Used in Compounding Under Section 503A — explains Category 1, Category 2 and the 503A bulks-list framework.
- RLS Russian Medicines Register, Selank 0.15% nasal drops — current Russian drug-reference entry listing registration information and non-prescription supply.
- Medicines and Healthcare products Regulatory Agency, Find product information about medicines — official UK medicine product-information search guidance.
- Health Products Regulatory Authority, Find a Medicine — Irish authorised-medicine search.